Helsinn and Riemser extend relationship in Germany
Sign licensing agreement for drug to prevent chemotherapy induced vomiting
Swiss pharmaceutical firm Helsinn Healthcare has granted marketing rights in Germany to Riemser Arzneimittel for a next-generation treatment in development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Riemser is the German licensee of Helsinn’s second-generation 5-HT3 receptor antagonist palonosetron,
The new product is a fixed-dose combination (in both oral and IV forms) containing netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron.
Under the terms of the agreement, Helsinn will handle all development activities (CMC, preclinical and clinical), obtaining regulatory approvals and holding the New Drug Application.
In addition, the firm will supply the product for commercial use in Germany.
